Trial Profile

Phase I Trial of the Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 08 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sorafenib (Primary) ; Temsirolimus (Primary)
Indications Liver cancer
Focus Adverse reactions; Biomarker

Most Recent Events

15 Jun 2017 Status changed from active, no longer recruiting to completed.
15 Jun 2017 Status changed from active, no longer recruiting to completed.
21 Jan 2017 Results of circulating tumor cells cohort from patients enrolled in two (NCT01008917, NCT01687673) trials (n=36) presented at the 2017 Gastrointestinal Cancers Symposium

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com